First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

NCT03492775 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Indolent Non-hodgkin Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Bendamustine

Sponsor

Prof. Dr. Wolfgang Hiddemann

Collaborators

[object Object]
[object Object]